



## Online Supplementary Material


Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting. *JHEOR*. 2024;11(2):41-48. [doi:10.36469/jheor.2024.121233](https://doi.org/10.36469/jheor.2024.121233)

### Figure S1: Patient Flowchart

This supplementary material has been provided by the authors to give readers additional information about their work.



**Supplementary Figure 1. Patient Flowchart**



ARSI: androgen receptor signaling inhibitor; FDA: Food and Drug Administration; mCSPC: metastatic castration-sensitive prostate cancer; nmCRPC: non-metastatic castration-resistant prostate cancer

**Notes:**

1. Agent identified at index date was based on medication dispensations only.
2. To confirm that patients were newly initiated on an ARSI as identified through dispensations, prescription information was examined to exclude patients with prescriptions for ARSIs other than apalutamide prior to the index date.
3. Continuous clinical activity was defined as the period from the first to last record in the clinical database. Patients with no observation period after the index date were excluded.